Facile One-Pot Synthesis of Benzo[h]isoquinolines via Strong Acid Triggered [1,2]-Sigmatropic Rearrangement: A Theoretical and Experimental Studies

V.M. BOITSOV^{1,2,*}, N.A. KNYAZEV^{1,3}, S.V. SHMAKOV¹, S.YU. VYAZMIN¹, D.M. NIKOLAEV¹, O.B. CHAKCHIR¹ and A.V. STEPANOV^{4,5,*}

¹Saint-Petersburg Academic University, St. Petersburg 194021, Russia

²Pavlov First Saint Petersburg State Medical University, St. Petersburg 197022, Russia

³Institute of Cytology of the Russian Academy of Science, St. Petersburg 194064, Russia

⁴Chemistry Department, Saint-Petersburg State University, St. Petersburg 198504, Russia

⁵Saint-Petersburg State Institute of Technology, St. Petersburg 190013, Russia

*Corresponding author: E-mail: bovitoli@yandex.ru, alstepakov@yandex.ru

Received: 13 March 2019;

Accepted: 12 June 2019;

Published online: 31 July 2019;

AJC-19511

Benzo[h]isoquinoline scaffold is of interest as a rigid subunit that can be useful for constructing biologically active products. However, no good-yielded synthetic pathway to this ring system has been reported yet. Herein, a facile one-pot synthesis from *N*-aryl itaconimides and 1,3-diarylisobenzofuran via strong acid triggered skeletal rearrangement reaction is described. Theoretical study for this rearrangement is provided at M11/cc-pVDZ level of theory. Antitumor activity of obtained benzo[h]isoquinoline derivatives against human erythroleukemia K562 cell line was evaluated *in vitro* by MTS-assay.

Keywords: Benzo[h]isoquinoline, *N*-Aryl Itaconimides, 1,3-Diarylisobenzofuran, Acid induced rearrangement, Antitumor activity.

INTRODUCTION

Efficient creation of structural, functional and stereochemical complexity from simple precursors is one of the most desired aspects of new synthetic methodology development. Pericyclic reactions are the powerful tool in organic synthesis and often simplify design complicated heterocyclic natural [1-6] and pharmacologically active compounds [7-13].

Benzo[h]isoquinoline scaffold appears in compounds displaying a broad range of biological activity: D1 dopamine agonists [14-16], serotonin (5-HT₂) receptor antagonists [17-19], histamine (H₃) receptor antagonists [20,21], inhibitors of Chk1 kinase [22] and c-Src inhibitors [23].

Due to such activity these substances have widely pharmaceutical implementation and are used in the treatment of Alzheimer's disease, Parkinson's disease, schizophrenia, memory disorder (including drug-induced memory disorder), movement disorder and central nervous system, treatment or prevention of central nervous disorders such as depressions, bipolar disorders, anxiety states, *etc.* cardiovascular disorders such as hypertension, throm-

bosis, stroke, *etc.* gastrointestinal disorders such as dysfunction of gastrointestinal tract motility.

On these grounds there is significant interest in the synthesis of benzo[h]isoquinoline ring systems and several multistage approaches have been reported [14-19,22,24-27]. Main disadvantage of all known methods is their multistage, that lead to low overall yield (about 10%). Two more articles were published last decade but these are rather the last step towards benzo[h]isoquinoline skeleton from bulky precursors: Klumpp *et al.* [28] have reported a novel synthetic method by the super acid-promoted cyclization of alkenyl-substituted *N*-heterocycles and Harrowven *et al.* [29] reported the first example of an intramolecular radical cyclisation of (Z)-azastilbenes, both in good yields.

EXPERIMENTAL

Hexane and ethyl acetate for the chromatography were distilled before use. IR spectra were obtained in KBr or CHCl₃ and wavelengths are reported in cm⁻¹. Melting points were determined on a Boetius instrument and are uncorrected. ¹H

and ^{13}C NMR spectra were recorded in CDCl_3 using Bruker Avance 400 spectrometer. Chemical shifts are reported in ppm relative to residual CHCl_3 (^1H , $\delta = 7.26$ ppm), CDCl_3 (^{13}C , $\delta = 77.17$ ppm) as internal standard. The X-ray diffraction data were performed by means of an Agilent Technologies SuperNova diffractometer with $\text{Cu-K}\alpha$ X-ray radiation. Reactions were monitored by TLC analysis using Silufol UV-254 plates. Thin layer chromatography was performed on silica gel 5-40 mesh eluted with ethyl acetate/hexane. HRMS spectra were obtained with a Bruker-micrOTOF and Bruker-maXis (QTOF). N-Aryl itaconimides were prepared following known procedures [30]. Analytical data for known compounds **3a-h** were identical with previously published data [31].

Typical procedure: A solution of 1,3-diphenylisobenzofuran (**2**) (1 mmol) and the corresponding imide **1** (1 mmol) in anhydrous dichloromethane (10 mL) was magnetically stirred for 48 h at room temperature. Methanesulfonic acid (6 mmol) was then added and the stirring was further maintained for 6 h at room temperature. After completion of the reaction (TLC-control), 10 mL of aq. Na_2CO_3 was added carefully to the reaction mixture. The aqueous layer was extracted with dichloromethane (3×5 mL), the organic layers were combined, dried over MgSO_4 and evaporated to dryness. The residue was then purified by preparative thin-layer chromatography using a mixture of hexane/ethyl acetate as eluent.

2-(4-Methylphenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3a): Pale-yellow solid, yield: 37 %; m.p. 238–240 °C; IR (KBr, ν_{max} , cm^{-1}): 700, 737, 769, 1212, 1372, 1510, 1687, 1726, 2851, 2921, 3029; ^1H NMR (400 MHz, CDCl_3) δ : 2.34 (s, 3H, Me), 7.00–7.70 (m, 20H, 18ArH + 2HC=); HRMS (ESI) calcd. (found) for $\text{C}_{32}\text{H}_{24}\text{NO}_2$ ($[\text{M}+\text{H}]^+$): 454.1807 (454.1809).

2-(4-Methoxyphenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3b): Pale-yellow solid, yield: 41 %; m.p.: > 260 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 740, 769, 839, 1032, 1164, 1230, 1373, 1509, 1686, 1725, 2927, 2998; ^1H NMR (400 MHz, CDCl_3) δ : 3.80 (s, 3H, MeO), 6.94 (d, 2H, $J = 9.0$ Hz, ArH), 7.05 (d, 2H, $J = 9.0$ Hz, ArH), 7.25–7.70 (m, 16H, 14ArH + 2HC=); ^{13}C NMR (100 MHz, CDCl_3) δ : 37.7, 55.8, 115.1 (2C), 121.1, 126.5, 126.8, 127.0, 127.4, 128.5 (2C), 128.7 (2C), 129.0 (2C), 129.2 (2C), 129.8 (2C), 129.9 (2C), 130.0 (2C), 133.3, 134.9, 137.8, 138.5, 140.2, 145.3, 159.8, 165.2, 170.7; HRMS (ESI) calcd. (found) for $\text{C}_{32}\text{H}_{24}\text{NO}_3$ ($[\text{M}+\text{H}]^+$): 470.1756 (470.1754).

2-(4-Fluorophenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3c): Yellow solid, yield: 52 %; m.p.: 156–158 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 740, 767, 830, 1152, 1237, 1372, 1508, 1697, 1715, 2919, 3057; ^1H NMR (400 MHz, CDCl_3) δ : 7.10 (br. s, 4H, ArH), 7.20–7.65 (m, 16H, 14ArH + 2HC=); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.4, 116.7 (d, $J = 22.6$ Hz, 2C), 118.5, 126.3, 126.8 (d, $J = 12.8$ Hz, 2C), 127.5, 128.4, 128.6 (2C), 128.9 (2C), 129.0 (2C), 129.2 (2C), 129.3, 129.8, 130.0, 133.4, 135.0, 137.7, 138.7, 140.2, 145.5, 146.7, 155.6, 165.1, 167.0 (d, $J = 406.8$ Hz), 172.2; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{21}\text{NO}_2\text{F}$ ($[\text{M}+\text{H}]^+$): 458.1556 (458.1550).

2-(4-Bromophenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3d): Pale-yellow solid, yield: 47 %; m.p.: 223–225 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 737, 770, 874,

1012, 1070, 1228, 1369, 1442, 1487, 1685, 1714, 2922, 3055; ^1H NMR (400 MHz, CDCl_3) δ : 7.03 (d, 2H, $J = 9.0$ Hz, ArH), 7.25–7.70 (m, 18H, 16ArH + 2HC=); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.4, 118.4, 120.7, 124.1, 126.5, 126.7, 126.9, 128.6 (2C), 128.8 (2C), 128.9 (2C), 129.0 (2C), 129.2 (2C), 129.8 (2C), 130.0, 132.9 (2C), 140.1, 142.1, 145.6, 146.7, 155.7, 164.3, 164.8, 170.2, 171.9; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{21}\text{NO}_2\text{Br}$ ($[\text{M}+\text{H}]^+$): 518.0756 (518.0751).

2-(3,5-Dichlorophenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3e): Pale-yellow solid, yield: 49 %; m.p.: 231–233 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 730.7, 763.6, 804.8, 1227.7, 1365.2, 1435.1, 1576.2, 1682.8, 1714.3, 3056. ^1H NMR (400 MHz, CDCl_3) δ : 6.50 (br. s, 1H, ArH), 7.07 (s, 2H, ArH), 7.25–7.70 (m, 16H, 14ArH + 2HC=); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.5, 118.1, 124.0, 126.7 (2C), 127.1, 127.7 (2C), 128.1 (2C), 128.2, 128.6 (2C), 128.8 (2C), 129.0, 129.3, 129.9 (2C), 130.0 (2C), 135.1, 135.7, 137.1, 138.2, 141.8, 147.0, 156.1, 163.9, 169.9, 171.7; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{20}\text{NO}_2\text{Cl}_2$ ($[\text{M}+\text{H}]^+$): 508.0871 (508.0863).

2-(4-Chloro-3-fluorophenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3f): Pale-yellow solid, yield: 57 %; m.p.: 220–222 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 893.4, 1077.9, 1230.9, 1260.9, 1369.4, 1445.6, 1496.8, 1624.6, 1681.6, 1712.1, 2920.9, 3051.6; ^1H NMR (400 MHz, CDCl_3) δ : 6.50 (br. s, 2H, ArH), 6.90–7.65 (m, 16H, 14ArH + 2HC=), 8.55 (br. s, 1H, ArH); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.5, 117.4 (d, $J = 22.6$ Hz), 118.2, 122.1 (d, $J = 19.6$ Hz), 124.0, 126.7 (2C), 128.5 (2C), 128.8 (4C), 129.0 (3C), 129.2 (3C), 129.3 (2C), 131.5, 133.7, 135.2, 138.3, 141.9, 146.9, 155.9, 158.0 (d, $J = 250.6$ Hz), 164.2, 171.9; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{20}\text{NO}_2\text{ClF}$ ($[\text{M}+\text{H}]^+$): 492.1167 (492.1165).

2-(3-Nitrophenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3g): Pale-yellow solid, yield: 69 %; m.p.: > 260 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 719.5, 744.6, 882.9, 1239.2, 1348.3, 1372.7, 1531.4, 1683.2, 1714.0, 3053.7; ^1H NMR (400 MHz, $\text{DMSO}-d_6$) δ : 6.70 (br. d, 2H, ArH), 7.20–7.50 (m, 13H, 11ArH + 2HC=), 7.65–7.85 (m, 2H, ArH), 8.17 (br. s, 1H, ArH), 8.32 (br. d, 2H, ArH); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.3, 119.0, 124.3, 125.0, 125.2, 127.1 (2C), 128.5, 129.0 (3C), 129.1 (2C), 129.2 (2C), 129.5 (2C), 129.6, 129.7, 131.2, 134.0, 135.4, 136.9, 137.3, 138.3, 142.7, 145.3, 149.0, 155.6, 164.1, 172.1; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{21}\text{N}_2\text{O}_4$ ($[\text{M}+\text{H}]^+$): 485.1501 (485.1505).

2-(3,4-Dichlorophenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3h): Pale-yellow solid, yield: 51 %; m.p.: 243–244 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 719, 741, 766, 824, 892, 1035, 1218, 1367, 1493, 1623, 1678, 1711, 2923, 3051; ^1H NMR (400 MHz, CDCl_3) δ : 6.52 (s, 2H, ArH), 7.01 (d, 1H, $J = 9.0$ Hz, ArH), 7.20–7.50 (m, 14H, 12ArH + 2HC=); 7.53 (d, 1H, $J = 9.0$ Hz, ArH), 8.53 (d, 1H, $J = 6.0$ Hz, ArH); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.5, 118.2, 124.0, 126.7 (2C), 128.5 (2C), 128.6 (2C), 128.8 (2C), 128.9 (2C), 129.0 (2C), 129.1 (2C), 129.3 (2C), 131.25, 131.27, 133.6, 133.7, 134.5, 135.1, 138.2, 141.9, 146.9, 156.0, 164.1, 171.8; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{20}\text{NO}_2\text{Cl}_2$ ($[\text{M}+\text{H}]^+$): 508.0871 (508.0866).

2-(3-Bromophenyl)-6,10b-diphenylbenzo[h]isoquinoline-1,3(2H,10bH)-dione (3i): Pale-yellow solid, yield: 47 %, m.p.: 233–234 °C; IR (KBr, ν_{max} , cm^{-1}): 703.1, 775.4, 1161.2,

1232.6, 1369.5, 1472.7, 1577.8, 1683.9, 1710.0, 1732.2, 3025.8, 3065.3; ^1H NMR (400 MHz, CDCl_3) δ : 6.51 (s, 2H, ArH), 7.15–7.50 (m, 17H, 15ArH + 2HC=); 8.50–8.60 (m, 1H, ArH); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.0, 118.0, 122.5, 123.6, 126.3 (2C), 127.5, 128.0, 128.2, 128.3, 128.5 (2C), 128.55 (2C), 128.58, 128.6, 128.8 (2C), 129.4, 129.6, 130.4, 131.9, 133.4, 134.8, 136.1, 137.9, 141.6, 146.4, 155.4, 163.9, 171.5; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{21}\text{NO}_2\text{Br}$ ($[\text{M}+\text{H}]^+$): 518.0750 (518.0752).

2-(3-Chlorophenyl)-6,10b-diphenylbenzo[*h*]isoquinoline-1,3(2H,10bH)-dione (3j): Pale-yellow solid, yield: 45 %, m.p.: 217–218 °C; IR (CHCl_3 , ν_{max} , cm^{-1}): 731.1, 777.4, 883.4, 1237.4, 1370.5, 1473.7, 1590.4, 1632.8, 1682.0, 1711.9, 3044.4; ^1H NMR (400 MHz, CDCl_3) δ : 6.52 (s, 2H, ArH), 7.00–7.50 (m, 17H, 15ArH + 2HC=); 8.55 (d, 1H, $J = 6.0$ Hz, ArH); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.0, 118.0, 123.6, 126.3 (2C), 127.0, 128.0, 128.3, 128.4, 128.45 (2C), 128.53, 128.55 (2C), 128.6, 128.8, 128.9 (2C), 129.0, 129.1, 130.1, 133.4, 134.8, 134.9, 136.0, 137.9, 141.6, 146.4, 155.4, 163.8, 171.5; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{21}\text{NO}_2\text{Cl}$ ($[\text{M}+\text{H}]^+$): 474.1255, (474.1258).

2-(4-Chlorophenyl)-6,10b-diphenylbenzo[*h*]isoquinoline-1,3(2H,10bH)-dione (3k): Pale-yellow solid, yield: 38 %; m.p.: > 260 °C; IR (KBr, ν_{max} , cm^{-1}): 700.5, 737.8, 766.7, 1089.8, 1227.7, 1370.5, 1490.1, 1561.4, 1683.9, 1727.3, 3031.1, 3062.2; ^1H NMR (400 MHz, CDCl_3) δ : 6.52 (s, 2H, ArH), 7.20–7.45 (m, 17H, 15ArH + 2HC=); 8.50–8.60 (m, 1H, ArH); ^{13}C NMR (100 MHz, CDCl_3) δ : 56.0, 123.7, 126.1, 126.3, 126.5, 127.2, 128.2 (2C), 128.3, 128.45, 128.55, 128.57 (2C), 128.7, 128.8, 129.4, 129.5 (2C), 129.6, 130.0 (2C), 132.9, 133.9, 134.4, 134.6, 137.3, 139.7, 145.1, 155.3, 164.0, 169.9; HRMS (ESI) calcd. (found) for $\text{C}_{31}\text{H}_{21}\text{NO}_2\text{Cl}$ ($[\text{M}+\text{H}]^+$): 474.1255 (474.1264).

Computational methodology: A number of minima and saddle points were located on the potential energy surface to obtain equilibrium structures and transition states. The double-ended anharmonic downward distortion following (D-ADDF) methodology was used for search of the transition states [32–35]. The types of all the stationary points found were confirmed by harmonic frequency calculations. The accessibility of products and reactants from a given transition state was confirmed by IRC calculations. Gibb's free energies were calculated at 273 K using energies and harmonic frequencies calculated in the previous step. Calculations were done at M11/cc-pVDZ (PCM = methanol) level of theory. The Gaussian 09 quantum chemistry software package [36] was used for all calculations except D-ADDF calculations for which we used our home-build code ReaNet.

Bioassay details: The human erythroleukemia K562 cell line was obtained from the Bank of Cell Cultures of the Institute of Cytology of Russian Academy of Sciences. Cells were cultured in RPMI-1640 medium (Thermo scientific, USA) with the addition of 10 % fetal calf serum (FCS) (Thermo-Scientific, USA) and 40 $\mu\text{g}/\text{mL}$ gentamicin (Sigma, USA).

MTS assay: A colorimetric MTS assay was used for assessing cell metabolic activity. This method is based on the reduction of 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium compound (MTS) to coloured and soluble in cell culture media formazan product by NAD(P)H-dependent dehydrogenase enzymes. Since this conversion and

such decrease of MTS can only occur in metabolically active cells, the level of activity is the measure of the viability of the cells. Shortly, cells were seeded in a 96-well microtiter plates at a density of 1×10^4 cells per well in 100 μL of complete medium and allowed to grow and adhere onto the wells during 24 h at 37 °C. After that the cells were treated with various concentrations of the compounds for a period of 48 h. After the treatment, 20 μL of MTS reagent was added into each well and incubated at 37 °C for 2 h. Finally the absorbance was recorded at 490 nm using 96 well plate reader "Multiskan GO" (Thermo Fisher Scientific, USA). For colored solutions the protocol was modified as followed: the absorbance was recorded directly before the addition of MTS reagent and measured values were further subtracted from final absorbance.

Statistical analysis: Significance of results was performed using Student T criterion. Statistical processing of results was performed using Origin Pro software. IC_{50} was calculated using Prism 6 for Windows. Differences between groups were considered significant at $p \leq 0.05$.

RESULTS AND DISCUSSION

Recently, spirocyclic Diels-Alder adducts of 1,3-diphenylisobenzofuran and N-aryl itaconimides by treatment with strong acid undergo a cascade of cationic rearrangement reactions leading to compounds with benzo[*h*]isoquinoline skeleton [31]. In this paper, we present facile one-pot synthesis of desired benzo[*h*]isoquinolines in moderate to good yields and theoretical investigation of undergoing reactions including [1,2]-sigmatropic rearrangement. *In vitro* antitumor activity of synthesized derivatives against K562 cell line was also evaluated.

The reactions of N-aryl itaconimides (**1a-i**) with 1,3-diarylisobenzofurans **2** in dichloromethane at room temperature followed by addition of methansulfonic acid (6 equiv.) led to the formation of desired benzo[*h*]isoquinolines (**3a-m**) and (**4l-m**) in moderate to good yields. The results are summarized in Table-1. The main advantage of presented one-pot procedure is the yield enhancement up to two-fold (compared with two-step procedure) as well as source and time-saving.

It should be noticed that cycloaddition to unsymmetrically substituted isobenzofuran occurs unspecifically and lead to the chromatographically inseparable 1:1 mixture of benzo[*h*]isoquinolines (Table-1, entries 12–13). Despite that it crystallizes from ethanol as 2:1 mixture as could be seen by X-ray diffraction analysis from 4-chlorophenyl substituent disorder: 70 % at position 10b benzo[*h*]isoquinoline structure (according to compound **3l**, marked as C12 at ORTEP representation) and 30 % at position 6 (compound **4l**, marked as C13 at ORTEP representation) (Fig. 1) [37]. Consecutive repeated recrystallization does not lead to further enrichment unfortunately.

Computational investigation of the reaction mechanisms: Based on the above results, a plausible mechanism for the formation of compounds **3(4)** is proposed and proved by theoretical calculation at M11/cc-pVDZ level of theory (**Scheme-I**). The calculated Gibb's free energy for the reagents, intermediates, transition states and possible products are given in **Scheme-I**. It was shown that [4+2]-cycloaddition of N-aryl itaconimides and 1,3-diphenylisobenzofurans proceeds stereoselectively with the formation of single diastereomer **5** as the

TABLE-1
ONE-POT SYNTHESIS OF SUBSTITUTED BENZO[*h*]ISOQUINOLINES (**3a-m, 4l-m**)

Entry	Ar ¹	Ar ²	Yield of products ^a (%)		Yield increment
			One-pot	Two steps ^b	
1	4-MeC ₆ H ₄	Ph	37 (3a)	20	1.85
2	4-MeOC ₆ H ₄	Ph	41 (3b)	23	1.78
3	4-FC ₆ H ₄	Ph	52 (3c)	28	1.86
4	4-BrC ₆ H ₄	Ph	47 (3d)	39	1.21
5	3,5-Cl ₂ C ₆ H ₃	Ph	49 (3e)	41	1.20
6	3-F,4-ClC ₆ H ₃	Ph	57 (3f)	33	1.73
7	3-O ₂ NC ₆ H ₄	Ph	69 (3g)	53	1.30
8	3,4-Cl ₂ C ₆ H ₃	Ph	51 (3h)	41	1.24
9	3-BrC ₆ H ₄	Ph	47 (3i)	—	—
10	3-ClC ₆ H ₄	Ph	45 (3j)	—	—
11	4-ClC ₆ H ₄	Ph	38 (3k)	—	—
12	3-ClC ₆ H ₄	4-ClC ₆ H ₄	48 (3l+4l) ^c	—	—
13	3,5-Cl ₂ C ₆ H ₃	4-ClC ₆ H ₄	53 (3m+4m) ^c	—	—

^aIsolated yield. ^bCalculated, based on our previously published results [Ref. 31]. ^cChromatographically inseparable mixture.

Scheme-I: Calculated reaction mechanism for the formation of **3(4)** and Gibbs free energies of the reagents, intermediates, transition states and products. All energies are given in kcal/mol

Fig. 1. ORTEP representation of co-crystallized **3i** and **4i** mixture

result of exo-orientation of reactants in the transition state [38]. The rearrangement of cycloadduct **5** starts with the formation of cation **6**. That further could transform *via* either the formation of intermediate alkenol **7** (pathway "a") or the formation of intermediate alkenol **11** (pathway "b"). Intermediate **7**, under acidic conditions, undergoes subsequent conversion into cation **9**. Followed 1,2-shift lead to intermediate **10**, which is converted into product **3(4)**. Intermediate **11** in his turn undergoes 1,2-shift to cation **12** firstly followed by subsequent conversion into cation **10a**, which is also converted into product **3(4)**. It should be noticed that the transformation of cation **7** to **8** as well as cation **12** to **13** proceeds as intramolecular 1,4-proton transfer with simultaneous C=C double bond formation. It is obvious from the calculations that pathway "a" (highlighted in green colour) is preferable: the excess of energy of 26.9 kcal/mol is satisfactory to reaction flow, while pathway "b" needs extra 17.7 kcal/mol.

Evaluation of cytotoxic activity: The antitumor activity of obtained compounds against human leukemia K562 cell line was evaluated *in vitro* by MTS assay. The results of these investigations are shown in Fig. 2. It was found that the most potent compound is **3i** bearing 3-bromophenyl substituent on benzo[*h*]isoquinoline moiety and its half maximal inhibitory concentration (IC₅₀) is 35.61 ± 0.06 µg/mL.

Conclusion

In conclusion, a facile source and time-saving synthetic method for construction of benzo[*h*]isoquinoline scaffold by one-pot synthesis from *N*-aryl itaconimides and 1,3-diaryliso-benzofuran *via* strong acid induced cascade of cationic rearrangement reactions is developed. The reaction mechanism has been studied at M11/cc-pVDZ level of theory. It was found that

Fig. 2. Cytotoxicity of synthesized compounds against human leukemia K562 cell line

the formation of desired products proceeds through cascade of cationic rearrangement reactions including [1,2]-sigmatropic rearrangement (1,2-carbonyl migration) with ring expansion. Additionally, the antitumor activity of synthesized compounds was evaluated by MTS assay *in vitro* against human leukemia K562 cell line.

ACKNOWLEDGEMENTS

This work was financially supported by the Ministry of Education and Science of Russian Federation 16.9790.2017/ BCh. This research made use of resources from the X-ray Diffraction Centre, Computer Center, Centre for Magnetic Resonance, Educational Resource Center of Chemistry, Centre for Chemical Analysis and Materials of Saint-Petersburg State University and the equipment of the shared research facilities of HPC computing resources at Lomonosov Moscow State University.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

1. B.B. Toure and D.G. Hall, *Chem. Rev.*, **109**, 4439 (2009); <https://doi.org/10.1021/cr800296p>.
2. K. Takao, R. Munakata and K. Tadano, *Chem. Rev.*, **105**, 4779 (2005); <https://doi.org/10.1021/cr040632u>.
3. I. Drutu, E.S. Krygowski and J.L. Wood, *J. Org. Chem.*, **66**, 7025 (2001); <https://doi.org/10.1021/jo015741c>.
4. G. Mehta and A. Srikrishna, *Chem. Rev.*, **97**, 671 (1997); <https://doi.org/10.1021/cr9403650>.
5. F.-P. Montforts, B. Gerlach and F. Hoepfer, *Chem. Rev.*, **94**, 327 (1994); <https://doi.org/10.1021/cr00026a003>.
6. F.-E. Chen and J. Huang, *Chem. Rev.*, **105**, 4671 (2005); <https://doi.org/10.1021/cr050521a>.
7. U. Kulesza, R. Sigüero, A. Mourino and R.R. Sicinski, *J. Org. Chem.*, **78**, 1444 (2013); <https://doi.org/10.1021/jo302513e>.
8. V. Singh, G.D. Praveena, K. Karki and Sh.M. Mobin, *J. Org. Chem.*, **72**, 2058 (2007); <https://doi.org/10.1021/jo062416m>.
9. H. McNab and R.G. Tyas, *J. Org. Chem.*, **72**, 8760 (2007); <https://doi.org/10.1021/jo0712502>.

10. T.M.V.D. Pinho e Melo, M.I.L. Soares, J.A. Paixão, A.M. Beja and M.R. Silva, *J. Org. Chem.*, **70**, 6629 (2005); <https://doi.org/10.1021/jo050480i>.
11. A.S. Filatov, N.A. Knyazev, A.P. Molchanov, T.L. Panikorovsky, R.R. Kostikov, A.G. Larina, V.M. Boitsov and A.V. Stepanov, *J. Org. Chem.*, **82**, 959 (2017); <https://doi.org/10.1021/acs.joc.6b02505>.
12. A.S. Filatov, N.A. Knyazev, M.N. Ryazantsev, V.V. Suslonov, A.G. Larina, A.P. Molchanov, R.R. Kostikov, V.M. Boitsov and A.V. Stepanov, *Org. Chem. Front.*, **5**, 595 (2018); <https://doi.org/10.1039/C7QO00888K>.
13. A.S. Filatov, N.A. Knyazev, S.V. Shmakov, A.A. Bogdanov, M.N. Ryazantsev, A.A. Shtyrov, G.L. Starova, A.P. Molchanov, A.G. Larina, V.M. Boitsov and A.V. Stepanov, *Synthesis*, **51**, 713 (2019); <https://doi.org/10.1055/s-0037-1611059>.
14. L.A. Bonner, B.R. Chemel, V.J. Watts and D.E. Nichols, *Bioorg. Med. Chem.*, **18**, 6763 (2010); <https://doi.org/10.1016/j.bmc.2010.07.052>.
15. J.G. Cannon, T. Lee, F.-L. Hsu, J.P. Long and J.R. Flynn, *J. Med. Chem.*, **23**, 502 (1980); <https://doi.org/10.1021/jm00179a006>.
16. D.E. Nichols and V.J. Watts, Patent WO 2010/124005 A1 (2010).
17. H. Stadler, J. Wichmann, A.J. Sleight and M. Bös, *Chimia*, **54**, 669 (2000).
18. M. Bös, H. Stadler, J. Wichmann, F. Jenck, J.R. Martin, J.-L. Moreau and A.J. Sleight, *Helv. Chim. Acta*, **81**, 525 (1998); <https://doi.org/10.1002/hlca.19980810306>.
19. M. Bös, H. Stadler and J. Wichmann, U.S. Patent 6,310,208 B1 (2001).
20. J.A. Diaz-Martin, B.E. Arenales and M.D. Jimenez Bargueno, U.S. Patent 7,678,807 B2 (2010).
21. J.A. Diaz-Martin, B.E. Arenales and M.D. Jimenez-Bargueno, Patent WO 2007/060027 A1 (2007).
22. R.M. Garbaccio, S. Huang, E.S. Tasber, M.E. Fraley, Y. Yan, S. Munshi, M. Ikuta, L. Kuo, C. Kreatsoulas, S. Stirdivant, B. Drakas, K. Rickert, E.S. Walsh, K.A. Hamilton, C.A. Buser, J. Hardwick, X. Mao, S.C. Beck, M.T. Abrams, W. Tao, R. Lobell, L. Sepp-Lorenzino and G.D. Hartman, *Bioorg. Med. Chem. Lett.*, **17**, 6280 (2007); <https://doi.org/10.1016/j.bmcl.2007.09.007>.
23. N. Atatreh, C. Stojkoski, P. Smith, G.W. Booker, C. Dive, A.D. Frenkel, S. Freeman and R.A. Bryce, *Bioorg. Med. Chem. Lett.*, **18**, 1217 (2008); <https://doi.org/10.1016/j.bmcl.2007.11.115>.
24. C.F. Koelsch and R.M. Lindquist, *J. Org. Chem.*, **21**, 657 (1956); <https://doi.org/10.1021/jo01112a018>.
25. M.S. Ledovskaya, A.P. Molchanov, R.R. Kostikov, T.L. Panikorovsky, V.V. Gurzhiy, M.N. Ryazantsev, V.M. Boitsov and A.V. Stepanov, *Tetrahedron*, **72**, 4827 (2016); <https://doi.org/10.1016/j.tet.2016.06.048>.
26. V. Mamane, F. Louërât, J. Iehl, M. Abboud and Y. Fort, *Tetrahedron*, **64**, 10699 (2008); <https://doi.org/10.1016/j.tet.2008.09.015>.
27. L. Castedo, M.M. Cid, J.A. Seijas and M.C. Villaverde, *Tetrahedron Lett.*, **32**, 3871 (1991); [https://doi.org/10.1016/S0040-4039\(00\)79400-7](https://doi.org/10.1016/S0040-4039(00)79400-7).
28. A. Li, T.M. Gilbert and D.A. Klumpp, *J. Org. Chem.*, **73**, 3654 (2008); <https://doi.org/10.1021/jo8003474>.
29. D.C. Harrowven, B.J. Sutton and S. Coulton, *Org. Biomol. Chem.*, **1**, 4047 (2003); <https://doi.org/10.1039/b309331j>.
30. V. Anand and V. Choudhary, *J. Appl. Polym. Sci.*, **82**, 2078 (2001); <https://doi.org/10.1002/app.2053>.
31. A.V. Stepanov, V.M. Boitsov, A.G. Larina and A.P. Molchanov, *Tetrahedron Lett.*, **55**, 4895 (2014); <https://doi.org/10.1016/j.tetlet.2014.06.107>.
32. S. Maeda, K. Ohno and K. Morokuma, *Phys. Chem. Chem. Phys.*, **15**, 3683 (2013); <https://doi.org/10.1039/c3cp44063j>.
33. D.S. Parker, B.B. Dangi, R.I. Kaiser, A. Jamal, M. Ryazantsev and K. Morokuma, *J. Phys. Chem. A*, **118**, 12111 (2014); <https://doi.org/10.1021/jp509990u>.
34. M.N. Ryazantsev, A. Jamal, S. Maeda and K. Morokuma, *Phys. Chem. Chem. Phys.*, **17**, 27789 (2015); <https://doi.org/10.1039/C5CP04329H>.
35. L.G. Muzangwa, T. Yang, D.S. Parker, R.I. Kaiser, A.M. Mebel, A. Jamal, M. Ryazantsev and K. Morokuma, *Phys. Chem. Chem. Phys.*, **17**, 7699 (2015); <https://doi.org/10.1039/C5CP00311C>.
36. M.J. Frisch, G.W. Trucks, H.B. Schlegel, G.E. Scuseria, M.A. Robb, J.R. Cheeseman, G. Scalmani, V. Barone, B. Mennucci, G.A. Petersson, H. Nakatsuji, M. Caricato, X. Li, H.P. Hratchian, A.F. Izmaylov, J. Bloino, G. Zheng, J.L. Sonnenberg, M. Hada, M. Ehara, K. Toyota, R. Fukuda, J. Hasegawa, M. Ishida, T. Nakajima, Y. Honda, O. Kitao, H. Nakai and T. Vreven Jr., J.A. Montgomery, J.E. Peralta, F. Ogliaro, M.J. Bearpark, J. Heyd, E.N. Brothers, K.N. Kudin, V.N. Staroverov, R. Kobayashi, J. Normand, K. Raghavachari, A.P. Rendell, J.C. Burant, S.S. Iyengar, J. Tomasi, M. Cossi, N. Rega, N.J. Millam, M. Klene, J.E. Knox, J.B. Cross, V. Bakken, C. Adamo, J. Jaramillo, R. Gomperts, R.E. Stratmann, O. Yazyev, A.J. Austin, R. Cammi, C. Pomelli, J.W. Ochterski, R.L. Martin, K. Morokuma, V.G. Zakrzewski, G.A. Voth, P. Salvador, J.J. Dannenberg, S. Dapprich, A.D. Daniels, O. Farkas, J.B. Foresman, J.V. Ortiz, J. Cioslowski, D.J. Fox, Gaussian 09, Revision A.01; Gaussian, Inc: Wallingford (2009).
37. Crystallographic data for the co-crystallized 3l and 4l mixture have been deposited with the Cambridge Crystallographic Data Centre as supplementary publication number CCDC 1882718. Copies of these data can be obtained on application to CCDC, 12 Union Road, Cambridge CB2 1EZ, UK (email: deposit@ccdc.cam.ac.uk).
38. A.P. Molchanov, A.V. Stepanov, V.M. Boitsov and R.R. Kostikov, *Russ. Chem. Bull.*, **62**, 1038 (2013); <https://doi.org/10.1007/s11172-013-0138-6>.